Prima picks up US patent for cancer treatment CVac
Prima BioMed (ASX:PRR) has secured a US patent covering its CVac cancer treatment technology.
The US Patent and Trademark Office (USPTO) has granted Prima’s application for a patent protecting the method of composition and use of CVac.
CVac production involves formulating the treatment using a patient’s own dendritic cells and then reinjecting it into the patient to generate a cytotoxic T cell response against mucin 1, an antigen found on the surface of cancer cells.
The USPTO has also granted a substantial term adjustment for the patent, extending its expiry date until August 2022.
“The grant of this key US patent with a patent term adjustment of almost four years is an important value proposition for Prima,” CEO Marc Voigt commented. “The patent term can potentially be further extended by up to five years if CVac receives market approval before it expires.”
Prima is currently developing CVac in ovarian cancer and recently commenced a phase II trial. CVac is also under development in pancreatic cancer.
The USPTO issued a notice of allowance for the patent application in May. Prima BioMed also has patents covering CVac in Australia, Canada, Europe and Japan.
Prima BioMed (ASX:PRR) shares were trading 10% higher at $0.044 as of around 1 pm on Wednesday.
AI-designed DNA switches flip genes on and off
The work creates the opportunity to turn the expression of a gene up or down in just one tissue...
Drug delays tumour growth in models of children's liver cancer
A new drug has been shown to delay the growth of tumours and improve survival in hepatoblastoma,...
Ancient DNA rewrites the stories of those preserved at Pompeii
Researchers have used ancient DNA to challenge long-held assumptions about the inhabitants of...
